^
Association details:
| Biomarker: | EML4-ALK fusion |
|---|---|
| Cancer: | Lung Non-Small Cell Squamous Cancer |
| Drug: | Alunbrig (brigatinib) (EGFR inhibitor, ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Acquired ALK Resistance Mutations Identified from Liquid Biopsy in an ALK-Rearranged Squamous Cell Lung Cancer Patient Treated with Sequential ALK TKI Therapy: A Case Report
Published date:
08/03/2021
Excerpt:
NGS revealed an EML4-ALK fusion (E6:A20) with a mutation allelic frequency (MAF) of 0.1% in the patient’s plasma ctDNA...The patient was then switched from crizotinib to brigatinib at a dose of 90 mg in the first week and 180 mg thereafter. The patient achieved a complete response (CR) for the lung lesion and a PR for the brain lesions...
DOI:
https://doi.org/10.2147/OTT.S315832
